Population-based analysis of factors associated with survival in patients undergoing cytoreductive nephrectomy in the targeted therapy era.


OBJECTIVES Despite level 1 evidence demonstrating a survival benefit of cytoreductive nephrectomy (CN) in well-selected patients with metastatic renal cell carcinoma (mRCC) in the cytokine era, its role in the contemporary period of targeted therapy remains understudied. To help facilitate improved patient selection for CN and clinical trial design in the… (More)
DOI: 10.1016/j.urolonc.2013.12.003

8 Figures and Tables


  • Presentations referencing similar topics